$
103.950
+0.43(0.415%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
105.080
Open
103.930
VWAP
104.07
Vol
1.40M
Mkt Cap
19.72B
Low
103.200
Amount
145.21M
EV/EBITDA(TTM)
--
Total Shares
163.12M
EV
19.65B
EV/OCF(TTM)
--
P/S(TTM)
46.95
Insmed Incorporated is a global biopharmaceutical company. The Company is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company’s pre-clinical research programs encompass a wide range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 as well as pre-clinical research programs.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
152.44M
+45.96%
--
--
113.94M
+21.96%
--
--
103.66M
+14.74%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for Insmed Incorporated (INSM) for FY2025, with the revenue forecasts being adjusted by -0.62% over the past three months. During the same period, the stock price has changed by 48.80%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.62%
In Past 3 Month
Stock Price
Go Up
up Image
+48.80%
In Past 3 Month
17 Analyst Rating
up Image
6.48% Upside
Wall Street analysts forecast INSM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INSM is 110.69 USD with a low forecast of 90.00 USD and a high forecast of 124.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
17 Buy
0 Hold
0 Sell
Strong Buy
up Image
6.48% Upside
Current: 103.950
sliders
Low
90.00
Averages
110.69
High
124.00
Wells Fargo
Tiago Fauth
Overweight
maintain
$119 -> $130
2025-07-22
New
Reason
Wells Fargo analyst Tiago Fauth raised the firm's price target on Insmed to $130 from $119 and keeps an Overweight rating on the shares. While literature directly linking NSP inhibition to clinical endpoints in CRSsNP is lacking, the firm sees merit in the approach and views the risk/reward as attractive, given low investor expectations and a meaningful market opportunity.
Morgan Stanley
Maxwell Skor
Overweight
maintain
$102 -> $108
2025-07-16
Reason
Morgan Stanley analyst Maxwell Skor raised the firm's price target on Insmed to $108 from $102 and keeps an Overweight rating on the shares as part of a Q2 earnings preview. The firm continues to view the potential brensocatib launch favorably. It cites increasing confidence into the potential bronchiectasis launch for the target bump.
JPMorgan
NULL
to
Overweight
upgrade
$90 -> $115
2025-07-08
Reason
JPMorgan raised the firm's price target on Insmed to $115 from $90 and keeps an Overweight rating on the shares. After meeting with management, the firm believes Insmed is on a "strong trajectory." It expects an on-time brensocatib approval in August.
JPMorgan
Overweight
upgrade
$90 -> $111
2025-07-08
Reason
JPMorgan raised the firm's price target on Insmed to $111 from $90 and keeps an Overweight rating on the shares. After meeting with management, the firm believes Insmed is on a "strong trajectory." It expects an on-time brensocatib approval in August.
Stifel
Stephen Willey
Buy
maintain
$92 -> $110
2025-06-11
Reason
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$90 -> $120
2025-06-11
Reason

Valuation Metrics

The current forward P/E ratio for Insmed Inc (INSM.O) is -20.54, compared to its 5-year average forward P/E of -8.92. For a more detailed relative valuation and DCF analysis to assess Insmed Inc 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-8.92
Current PE
-20.54
Overvalued PE
-4.61
Undervalued PE
-13.23

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-10.13
Current EV/EBITDA
-22.53
Overvalued EV/EBITDA
-5.56
Undervalued EV/EBITDA
-14.71

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Strongly Overvalued
5Y Average PS
16.51
Current PS
36.40
Overvalued PS
25.34
Undervalued PS
7.69

Financials

Annual
Quarterly
FY2025Q1
YoY :
+22.94%
92.82M
Total Revenue
FY2025Q1
YoY :
+46.02%
-229.84M
Operating Profit
FY2025Q1
YoY :
+63.33%
-256.58M
Net Income after Tax
FY2025Q1
YoY :
+33.96%
-1.42
EPS - Diluted
FY2025Q1
YoY :
+44.22%
-272.16M
Free Cash Flow
FY2025Q1
YoY :
+0.68%
75.72
Gross Profit Margin - %
FY2025Q1
YoY :
+11.04%
-207.14
FCF Margin - %
FY2025Q1
YoY :
+32.85%
-276.42
Net Margin - %

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
60.9M
USD
41
3-6
Months
37.6M
USD
25
6-9
Months
18.2M
USD
31
0-12
Months
25.6M
USD
8
Bought
0-3
2
201.7K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
310.2K
Volume
4
6-9
Months
2.4M
Volume
12
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
8
2.5M
Volume
Months
6-9
10
4.8M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
8.0K
USD
1
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
1
8.0K
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months

INSM News & Events

Events Timeline

2025-06-12 (ET)
2025-06-12
05:56:57
Insmed 7.812M share Spot Secondary priced at $96.00
select
2025-06-11 (ET)
2025-06-11
16:06:16
Insmed announces $650M common stock offering
select
2025-06-10 (ET)
2025-06-10
08:54:38
Liquidia falls after Insmed's TPIP meets endpoints in study
select
Sign Up For More Events

News

9.5
07-24PRnewswire
PinnedInsmed to Host Second-Quarter 2025 Financial Results Conference Call on Thursday, August 7, 2025
3.0
07-15NASDAQ.COM
INSM Quantitative Stock Analysis
6.5
07-10Benzinga
Cramer Says Tesla Dominates While Ouster Is 'Too Speculative'
Sign Up For More News

FAQ

arrow icon

What is Insmed Inc (INSM) stock price today?

The current price of INSM is 103.95 USD — it has increased 0.42 % in the last trading day.

arrow icon

What is Insmed Inc (INSM)'s business?

arrow icon

What is the price predicton of INSM Stock?

arrow icon

What is Insmed Inc (INSM)'s revenue for the last quarter?

arrow icon

What is Insmed Inc (INSM)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Insmed Inc (INSM)'s fundamentals?

arrow icon

How many employees does Insmed Inc (INSM). have?

arrow icon

What is Insmed Inc (INSM) market cap?